NDC 16571-767

Darifenacin

Darifenacin

Darifenacin is a Oral Tablet, Film Coated, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Rising Pharma Holdings, Inc.. The primary component is Darifenacin Hydrobromide.

Product ID16571-767_e2aa9544-0136-463d-a73b-1a299534446a
NDC16571-767
Product TypeHuman Prescription Drug
Proprietary NameDarifenacin
Generic NameDarifenacin
Dosage FormTablet, Film Coated, Extended Release
Route of AdministrationORAL
Marketing Start Date2016-09-19
Marketing CategoryANDA /
Application NumberANDA206743
Labeler NameRising Pharma Holdings, Inc.
Substance NameDARIFENACIN HYDROBROMIDE
Active Ingredient Strength8 mg/1
Pharm ClassesCholinergic Muscarinic Antagonist [EPC],Cholinergic Muscarinic Antagonists [MoA]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 16571-767-03

30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (16571-767-03)
Marketing Start Date2016-09-19
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Darifenacin" or generic name "Darifenacin"

NDCBrand NameGeneric Name
0591-4375Darifenacindarifenacin
0591-4380Darifenacindarifenacin
13668-202DarifenacinDarifenacin
13668-203DarifenacinDarifenacin
16571-767DarifenacinDarifenacin
16571-768DarifenacinDarifenacin
33342-276DarifenacinDarifenacin
33342-277DarifenacinDarifenacin
46708-223DARIFENACINDARIFENACIN
46708-224DARIFENACINDARIFENACIN
52605-067DarifenacinDarifenacin Hydrobromide
52605-068DarifenacinDarifenacin Hydrobromide
59746-516darifenacindarifenacin hydrobromide
59746-517darifenacindarifenacin hydrobromide
62332-223DARIFENACINDARIFENACIN
69097-432DarifenacinDarifenacin
69097-431DarifenacinDarifenacin
62332-224DARIFENACINDARIFENACIN
65862-862DarifenacinDarifenacin
65862-861DarifenacinDarifenacin
0430-0170Enablexdarifenacin
0430-0171Enablexdarifenacin

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.